A Dual Read-Out Assay to Evaluate the Potency of Compounds Active against Mycobacterium tuberculosis
Open Access
- 4 April 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (4), e60531
- https://doi.org/10.1371/journal.pone.0060531
Abstract
Tuberculosis is a serious global health problem caused by the bacterium Mycobacterium tuberculosis . There is an urgent need for discovery and development of new treatments, but this can only be accomplished through rapid and reproducible M. tuberculosis assays designed to identify potent inhibitors. We developed an automated 96-well assay utilizing a recombinant strain of M. tuberculosis expressing a far-red fluorescent reporter to determine the activity of novel compounds; this allowed us to measure growth by monitoring both optical density and fluorescence. We determined that optical density and fluorescence were correlated with cell number during logarithmic phase growth. Fluorescence was stably maintained without antibiotic selection over 5 days, during which time cells remained actively growing. We optimized parameters for the assay, with the final format being 5 days’ growth in 96-well plates in the presence of 2% w/v DMSO. We confirmed reproducibility using rifampicin and other antibiotics. The dual detection method allows for a reproducible calculation of the minimum inhibitory concentration (MIC), at the same time detecting artefacts such as fluorescence quenching or compound precipitation. We used our assay to confirm anti-tubercular activity and establish the structure activity relationship (SAR) around the imidazo[1,2- a ]pyridine-3-carboxamides, a promising series of M. tuberculosis inhibitors.Keywords
This publication has 30 references indexed in Scilit:
- Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824Antimicrobial Agents and Chemotherapy, 2012
- Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffoldsBioorganic & Medicinal Chemistry, 2012
- Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescenceJournal of Antimicrobial Chemotherapy, 2011
- High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37RvTuberculosis, 2011
- Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis ActivityACS Medicinal Chemistry Letters, 2011
- A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacyNature Communications, 2010
- Antituberculosis activity of the molecular libraries screening center network libraryTuberculosis, 2009
- High-throughput screening for inhibitors of Mycobacterium tuberculosis H37RvTuberculosis, 2009
- Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trialThe Lancet, 2009
- Rapid Microbiologic and Pharmacologic Evaluation of Experimental Compounds against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2006